Daniel Mark Blumenthal, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Faculty, Medical | 10 | 2020 | 1181 | 1.980 |
Why?
|
Schools, Medical | 7 | 2020 | 880 | 1.410 |
Why?
|
Medicare Part C | 3 | 2022 | 296 | 1.310 |
Why?
|
Career Mobility | 4 | 2020 | 262 | 1.270 |
Why?
|
Physicians, Women | 7 | 2020 | 486 | 1.220 |
Why?
|
Angina Pectoris | 2 | 2021 | 977 | 1.070 |
Why?
|
Internal Medicine | 4 | 2019 | 1009 | 0.860 |
Why?
|
Reimbursement, Incentive | 3 | 2018 | 540 | 0.830 |
Why?
|
Sex Distribution | 5 | 2019 | 2297 | 0.830 |
Why?
|
Reimbursement Mechanisms | 2 | 2018 | 670 | 0.800 |
Why?
|
Medicare | 14 | 2021 | 6566 | 0.800 |
Why?
|
Hospital Mortality | 8 | 2019 | 5317 | 0.700 |
Why?
|
Mandatory Reporting | 2 | 2018 | 121 | 0.690 |
Why?
|
Coronary Artery Disease | 6 | 2021 | 6487 | 0.680 |
Why?
|
Prescriptions | 1 | 2021 | 387 | 0.660 |
Why?
|
Quality of Health Care | 7 | 2018 | 4371 | 0.650 |
Why?
|
Contract Services | 1 | 2017 | 94 | 0.610 |
Why?
|
Allergy and Immunology | 1 | 2019 | 169 | 0.610 |
Why?
|
Salaries and Fringe Benefits | 2 | 2017 | 264 | 0.600 |
Why?
|
Myocardial Infarction | 6 | 2018 | 11727 | 0.600 |
Why?
|
Biopharmaceutics | 1 | 2016 | 22 | 0.580 |
Why?
|
Leadership | 4 | 2020 | 1357 | 0.570 |
Why?
|
Hospitals | 5 | 2018 | 3952 | 0.570 |
Why?
|
Health Care Reform | 2 | 2024 | 1261 | 0.560 |
Why?
|
United States | 42 | 2024 | 69872 | 0.560 |
Why?
|
Episode of Care | 1 | 2016 | 126 | 0.540 |
Why?
|
Hospitals, Proprietary | 1 | 2015 | 39 | 0.530 |
Why?
|
Prescription Fees | 1 | 2016 | 146 | 0.530 |
Why?
|
Hospitalists | 2 | 2018 | 305 | 0.510 |
Why?
|
Foreign Medical Graduates | 3 | 2021 | 79 | 0.500 |
Why?
|
Arthroplasty, Replacement | 1 | 2018 | 339 | 0.490 |
Why?
|
Certification | 1 | 2017 | 424 | 0.480 |
Why?
|
Hypolipidemic Agents | 1 | 2017 | 604 | 0.440 |
Why?
|
Ownership | 1 | 2015 | 332 | 0.440 |
Why?
|
Program Development | 3 | 2014 | 1316 | 0.420 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 413 | 0.420 |
Why?
|
Drug Costs | 2 | 2017 | 1105 | 0.420 |
Why?
|
Interviews as Topic | 1 | 2018 | 2539 | 0.400 |
Why?
|
Angina, Unstable | 1 | 2016 | 926 | 0.400 |
Why?
|
Hospital Costs | 1 | 2017 | 985 | 0.390 |
Why?
|
Patient Readmission | 7 | 2019 | 3114 | 0.390 |
Why?
|
Economics, Hospital | 1 | 2013 | 213 | 0.380 |
Why?
|
Appetite Regulation | 1 | 2010 | 88 | 0.360 |
Why?
|
Sex Factors | 7 | 2020 | 10397 | 0.360 |
Why?
|
Nervous System Physiological Phenomena | 1 | 2010 | 117 | 0.350 |
Why?
|
Drug-Eluting Stents | 1 | 2016 | 753 | 0.340 |
Why?
|
Health Care Costs | 3 | 2019 | 3209 | 0.330 |
Why?
|
Coronary Artery Bypass | 1 | 2018 | 2289 | 0.330 |
Why?
|
Motivation | 1 | 2018 | 1971 | 0.330 |
Why?
|
Hospitalization | 4 | 2019 | 10262 | 0.320 |
Why?
|
Physicians | 7 | 2021 | 4567 | 0.320 |
Why?
|
Critical Care | 2 | 2017 | 2647 | 0.300 |
Why?
|
Curriculum | 3 | 2016 | 3605 | 0.290 |
Why?
|
Colonoscopy | 1 | 2015 | 1367 | 0.290 |
Why?
|
Length of Stay | 2 | 2017 | 6309 | 0.270 |
Why?
|
Cross-Sectional Studies | 11 | 2021 | 25043 | 0.270 |
Why?
|
Fee-for-Service Plans | 4 | 2019 | 694 | 0.270 |
Why?
|
Health Expenditures | 1 | 2018 | 2348 | 0.270 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5319 | 0.260 |
Why?
|
Primary Health Care | 1 | 2021 | 4558 | 0.250 |
Why?
|
Behavior, Addictive | 1 | 2010 | 462 | 0.250 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3843 | 0.240 |
Why?
|
Patient Compliance | 1 | 2015 | 2684 | 0.240 |
Why?
|
Humans | 55 | 2024 | 744343 | 0.230 |
Why?
|
Quality Improvement | 2 | 2018 | 3749 | 0.230 |
Why?
|
Coronary Angiography | 1 | 2015 | 4577 | 0.230 |
Why?
|
Male | 38 | 2023 | 350118 | 0.220 |
Why?
|
Electronic Health Records | 3 | 2023 | 4468 | 0.210 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 2291 | 0.210 |
Why?
|
Quality Assurance, Health Care | 4 | 2019 | 2212 | 0.210 |
Why?
|
Female | 38 | 2023 | 380194 | 0.210 |
Why?
|
Clinical Competence | 4 | 2021 | 4687 | 0.200 |
Why?
|
Risk Assessment | 6 | 2018 | 23338 | 0.200 |
Why?
|
Subtilisins | 1 | 2021 | 83 | 0.200 |
Why?
|
Patient Care Team | 1 | 2013 | 2531 | 0.200 |
Why?
|
Aged | 26 | 2021 | 163280 | 0.190 |
Why?
|
Insurance Coverage | 2 | 2022 | 1901 | 0.180 |
Why?
|
Cardiovascular Diseases | 3 | 2021 | 15165 | 0.180 |
Why?
|
Internship and Residency | 3 | 2019 | 5788 | 0.170 |
Why?
|
Endoribonucleases | 1 | 2021 | 229 | 0.170 |
Why?
|
Cost Control | 1 | 2022 | 624 | 0.170 |
Why?
|
Golf | 1 | 2018 | 16 | 0.170 |
Why?
|
Medicine | 2 | 2020 | 946 | 0.170 |
Why?
|
Health Benefit Plans, Employee | 1 | 2022 | 332 | 0.170 |
Why?
|
Health Facility Size | 1 | 2018 | 64 | 0.160 |
Why?
|
Professional Misconduct | 1 | 2018 | 73 | 0.160 |
Why?
|
Talin | 1 | 2018 | 44 | 0.160 |
Why?
|
Fraud | 1 | 2018 | 67 | 0.160 |
Why?
|
Vinculin | 1 | 2018 | 62 | 0.160 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5137 | 0.160 |
Why?
|
Immunological Synapses | 1 | 2018 | 54 | 0.150 |
Why?
|
Integrin alpha4beta1 | 1 | 2018 | 121 | 0.150 |
Why?
|
Feeding Behavior | 1 | 2010 | 3188 | 0.150 |
Why?
|
Gynecology | 1 | 2023 | 513 | 0.150 |
Why?
|
Aged, 80 and over | 10 | 2021 | 57776 | 0.150 |
Why?
|
Odds Ratio | 3 | 2020 | 9849 | 0.150 |
Why?
|
Professional Practice Location | 1 | 2017 | 59 | 0.150 |
Why?
|
Industry | 1 | 2019 | 365 | 0.150 |
Why?
|
Equipment and Supplies | 1 | 2019 | 281 | 0.140 |
Why?
|
Medicare Part D | 1 | 2021 | 328 | 0.140 |
Why?
|
Evidence-Based Practice | 2 | 2019 | 500 | 0.140 |
Why?
|
Community-Based Participatory Research | 1 | 2018 | 214 | 0.140 |
Why?
|
Age Distribution | 3 | 2018 | 2902 | 0.140 |
Why?
|
Cardiology Service, Hospital | 1 | 2018 | 246 | 0.130 |
Why?
|
Efficiency | 1 | 2018 | 462 | 0.130 |
Why?
|
Multivariate Analysis | 3 | 2020 | 12245 | 0.130 |
Why?
|
Heart Failure | 2 | 2019 | 10900 | 0.130 |
Why?
|
Specialization | 2 | 2018 | 777 | 0.130 |
Why?
|
Achievement | 1 | 2016 | 291 | 0.130 |
Why?
|
Public Sector | 1 | 2016 | 265 | 0.130 |
Why?
|
Middle Aged | 18 | 2020 | 213383 | 0.120 |
Why?
|
Secondary Prevention | 1 | 2021 | 1530 | 0.120 |
Why?
|
Emigration and Immigration | 1 | 2017 | 404 | 0.120 |
Why?
|
Acute Coronary Syndrome | 2 | 2018 | 2337 | 0.120 |
Why?
|
Prescription Drugs | 1 | 2021 | 595 | 0.120 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2017 | 501 | 0.120 |
Why?
|
Congresses as Topic | 1 | 2018 | 764 | 0.110 |
Why?
|
Hospitals, Teaching | 1 | 2018 | 1179 | 0.110 |
Why?
|
Public Policy | 1 | 2017 | 572 | 0.110 |
Why?
|
Employee Performance Appraisal | 1 | 2013 | 87 | 0.110 |
Why?
|
Emergency Medicine | 2 | 2019 | 1207 | 0.110 |
Why?
|
Health Facilities | 1 | 2017 | 573 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20129 | 0.100 |
Why?
|
Retrospective Studies | 8 | 2019 | 77449 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1147 | 0.100 |
Why?
|
Patient Satisfaction | 2 | 2015 | 3396 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2020 | 880 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2016 | 789 | 0.100 |
Why?
|
Adult | 15 | 2023 | 214055 | 0.090 |
Why?
|
Dyspnea | 1 | 2018 | 1303 | 0.090 |
Why?
|
Health Personnel | 1 | 2024 | 3218 | 0.090 |
Why?
|
Exercise Test | 1 | 2018 | 2074 | 0.090 |
Why?
|
Health Services Research | 4 | 2018 | 1836 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2021 | 1876 | 0.090 |
Why?
|
Angioplasty | 1 | 2012 | 364 | 0.090 |
Why?
|
Patient Care Management | 1 | 2013 | 306 | 0.090 |
Why?
|
Anticholesteremic Agents | 1 | 2016 | 979 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 13408 | 0.090 |
Why?
|
Publishing | 1 | 2016 | 833 | 0.080 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 2540 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2018 | 5078 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6459 | 0.080 |
Why?
|
Job Satisfaction | 1 | 2012 | 535 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39050 | 0.080 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5524 | 0.070 |
Why?
|
Natural Language Processing | 1 | 2015 | 1041 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4838 | 0.070 |
Why?
|
Cholesterol, LDL | 1 | 2016 | 2356 | 0.070 |
Why?
|
General Surgery | 1 | 2018 | 1636 | 0.070 |
Why?
|
Medicaid | 2 | 2019 | 2736 | 0.070 |
Why?
|
Quality of Life | 2 | 2018 | 12804 | 0.070 |
Why?
|
Program Evaluation | 1 | 2014 | 2488 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2018 | 1797 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4386 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5391 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2018 | 15295 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2017 | 3679 | 0.060 |
Why?
|
Drug Industry | 2 | 2021 | 746 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15226 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2759 | 0.060 |
Why?
|
Survival Rate | 1 | 2018 | 12788 | 0.060 |
Why?
|
Metabolic Diseases | 1 | 2010 | 658 | 0.060 |
Why?
|
Food | 1 | 2008 | 771 | 0.060 |
Why?
|
Radiology | 1 | 2017 | 2100 | 0.060 |
Why?
|
Commerce | 1 | 2008 | 592 | 0.060 |
Why?
|
Food Supply | 1 | 2008 | 524 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2015 | 3589 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2018 | 63114 | 0.050 |
Why?
|
Pilot Projects | 1 | 2014 | 8324 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3255 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 9959 | 0.050 |
Why?
|
Prognosis | 2 | 2018 | 29063 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 7913 | 0.050 |
Why?
|
Ribonucleases | 1 | 2021 | 287 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9274 | 0.040 |
Why?
|
Depression | 1 | 2018 | 7766 | 0.040 |
Why?
|
Databases, Factual | 3 | 2018 | 7729 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7659 | 0.040 |
Why?
|
Paxillin | 1 | 2018 | 86 | 0.040 |
Why?
|
Community Health Planning | 1 | 2018 | 165 | 0.040 |
Why?
|
Cohort Studies | 4 | 2023 | 40561 | 0.040 |
Why?
|
Health Services Misuse | 1 | 2018 | 243 | 0.040 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2018 | 378 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2018 | 743 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2021 | 970 | 0.030 |
Why?
|
Lipoproteins, LDL | 1 | 2019 | 640 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 707 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2019 | 705 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2018 | 1155 | 0.030 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 4258 | 0.030 |
Why?
|
Tyrosine | 1 | 2018 | 1461 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 1240 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2019 | 924 | 0.030 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2018 | 554 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 1518 | 0.030 |
Why?
|
Time Factors | 3 | 2019 | 40075 | 0.030 |
Why?
|
Canada | 1 | 2016 | 2065 | 0.020 |
Why?
|
Models, Molecular | 1 | 2021 | 5456 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3444 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18370 | 0.020 |
Why?
|
Chest Pain | 1 | 2018 | 1114 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1003 | 0.020 |
Why?
|
Actins | 1 | 2018 | 2121 | 0.020 |
Why?
|
Stents | 1 | 2021 | 3280 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2016 | 1660 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2020 | 2585 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2021 | 3068 | 0.020 |
Why?
|
Connecticut | 1 | 2008 | 366 | 0.020 |
Why?
|
Cardiology | 1 | 2019 | 1668 | 0.020 |
Why?
|
Incidence | 2 | 2016 | 20947 | 0.020 |
Why?
|
Cell Line | 1 | 2021 | 15997 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8436 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2017 | 2266 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9687 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2019 | 2208 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3610 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10388 | 0.020 |
Why?
|
Education, Medical | 1 | 2016 | 1721 | 0.020 |
Why?
|
Blood Pressure | 1 | 2019 | 8554 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10252 | 0.010 |
Why?
|
Vegetables | 1 | 2008 | 1182 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7279 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16689 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5751 | 0.010 |
Why?
|
Risk Factors | 2 | 2018 | 72290 | 0.010 |
Why?
|
Income | 1 | 2008 | 1913 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2008 | 2050 | 0.010 |
Why?
|
Animals | 1 | 2010 | 168757 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19905 | 0.010 |
Why?
|
Health Policy | 1 | 2008 | 2661 | 0.010 |
Why?
|
Signal Transduction | 1 | 2018 | 23403 | 0.010 |
Why?
|
Prospective Studies | 1 | 2018 | 53288 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 56430 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 85781 | 0.010 |
Why?
|